I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 21% ± 4% | |
| glutamatergic neuron | 3 studies | 26% ± 5% | |
| endothelial cell | 3 studies | 16% ± 1% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| GABAergic neuron | 3 studies | 21% ± 4% | |
| glutamatergic neuron | 3 studies | 26% ± 5% | |
| endothelial cell | 3 studies | 16% ± 1% |
Insufficient scRNA-seq data for expression of RSAD2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| breast | 97% | 521.28 | 447 / 459 | 92% | 32.67 | 1028 / 1118 |
| ovary | 98% | 384.26 | 177 / 180 | 90% | 24.40 | 385 / 430 |
| lung | 100% | 830.54 | 577 / 578 | 81% | 15.22 | 934 / 1155 |
| uterus | 99% | 432.70 | 168 / 170 | 78% | 24.57 | 359 / 459 |
| thymus | 94% | 354.35 | 612 / 653 | 81% | 9.57 | 489 / 605 |
| pancreas | 81% | 139.62 | 266 / 328 | 88% | 16.88 | 156 / 178 |
| esophagus | 82% | 347.05 | 1192 / 1445 | 83% | 21.38 | 151 / 183 |
| adrenal gland | 95% | 395.93 | 246 / 258 | 66% | 14.99 | 152 / 230 |
| brain | 91% | 519.51 | 2396 / 2642 | 70% | 15.31 | 496 / 705 |
| intestine | 99% | 420.73 | 960 / 966 | 56% | 8.36 | 293 / 527 |
| bladder | 90% | 231.10 | 19 / 21 | 64% | 16.72 | 322 / 504 |
| stomach | 83% | 329.16 | 298 / 359 | 66% | 9.47 | 189 / 286 |
| kidney | 89% | 495.73 | 79 / 89 | 60% | 6.53 | 543 / 901 |
| prostate | 96% | 325.77 | 234 / 245 | 43% | 5.04 | 217 / 502 |
| spleen | 100% | 746.90 | 241 / 241 | 0% | 0 | 0 / 0 |
| adipose | 95% | 594.27 | 1147 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 29.55 | 42 / 45 |
| heart | 89% | 299.97 | 762 / 861 | 0% | 0 | 0 / 0 |
| muscle | 85% | 210.91 | 686 / 803 | 0% | 0 | 0 / 0 |
| peripheral blood | 84% | 829.68 | 777 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 82% | 294.18 | 1096 / 1335 | 0% | 0 | 0 / 0 |
| skin | 31% | 62.02 | 559 / 1809 | 48% | 7.81 | 226 / 472 |
| liver | 46% | 112.52 | 105 / 226 | 24% | 2.68 | 96 / 406 |
| lymph node | 0% | 0 | 0 / 0 | 41% | 9.36 | 12 / 29 |
| eye | 0% | 0 | 0 / 0 | 8% | 0.69 | 6 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0045071 | Biological process | negative regulation of viral genome replication |
| GO_0045087 | Biological process | innate immune response |
| GO_0009615 | Biological process | response to virus |
| GO_0051607 | Biological process | defense response to virus |
| GO_0034157 | Biological process | positive regulation of toll-like receptor 7 signaling pathway |
| GO_0050709 | Biological process | negative regulation of protein secretion |
| GO_2000553 | Biological process | positive regulation of T-helper 2 cell cytokine production |
| GO_0035710 | Biological process | CD4-positive, alpha-beta T cell activation |
| GO_0034165 | Biological process | positive regulation of toll-like receptor 9 signaling pathway |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0043367 | Biological process | CD4-positive, alpha-beta T cell differentiation |
| GO_0005811 | Cellular component | lipid droplet |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005743 | Cellular component | mitochondrial inner membrane |
| GO_0001650 | Cellular component | fibrillar center |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0005741 | Cellular component | mitochondrial outer membrane |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0016829 | Molecular function | lyase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0051539 | Molecular function | 4 iron, 4 sulfur cluster binding |
| Gene name | RSAD2 |
| Protein name | S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (SAND) (EC 4.2.-.-) (Cytomegalovirus-induced gene 5 protein) (Radical S-adenosyl methionine domain-containing protein 2) (Virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible) (Viperin) Radical S-adenosyl methionine domain containing 2 |
| Synonyms | CIG5 |
| Description | FUNCTION: Interferon-inducible antiviral protein which plays a major role in the cell antiviral state induced by type I and type II interferon . Catalyzes the conversion of cytidine triphosphate (CTP) to 3'-deoxy-3',4'-didehydro-CTP (ddhCTP) via a SAM-dependent radical mechanism . In turn, ddhCTP acts as a chain terminator for the RNA-dependent RNA polymerases from multiple viruses and directly inhibits viral replication . Therefore, inhibits a wide range of DNA and RNA viruses, including human cytomegalovirus (HCMV), hepatitis C virus (HCV), west Nile virus (WNV), dengue virus, sindbis virus, influenza A virus, sendai virus, vesicular stomatitis virus (VSV), zika virus, and human immunodeficiency virus (HIV-1) . Promotes also TLR7 and TLR9-dependent production of IFN-beta production in plasmacytoid dendritic cells (pDCs) by facilitating 'Lys-63'-linked ubiquitination of IRAK1 by TRAF6 . Plays a role in CD4+ T-cells activation and differentiation. Facilitates T-cell receptor (TCR)-mediated GATA3 activation and optimal T-helper 2 (Th2) cytokine production by modulating NFKB1 and JUNB activities. Can inhibit secretion of soluble proteins. . |
| Accessions | Q8WXG1 ENST00000382040.4 ENST00000679863.1 ENST00000679373.1 ENST00000680607.1 C9J674 ENST00000680320.1 A0A7P0TA11 A0A7P0T918 A0A7P0Z4E2 ENST00000442639.6 |
